Gables Capital Management’s BioStem Technologies BSEM Stock Holding History

Gables Capital Management’s Portfolio BSEM Stock Details BSEM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.08K	Buy	+350	New	+$1.33K	﹤0.01%	475

Other funds holding BSEM

PNC Financial Services Group Pittsburgh, Pennsylvania $191B AUM 30.51% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Anson Funds Management Dallas, Texas $1.82B AUM 38.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

StoneX Group New York $2.75B AUM 24.13% 1-Year Est. Return

Elequin Capital New York $1.47B AUM 5.26% 1-Year Est. Return

Ashton Thomas Private Wealth Scottsdale, Arizona $4.98B AUM 21.09% 1-Year Est. Return

Vanguard Global Advisers Malvern, Pennsylvania $225B AUM

Gables Capital Management's BSEM Position: Q3 2026 in Review

Gables Capital Management opened a new position in BioStem Technologies (BSEM) in Q3 2026: 350 shares worth $1.08K. The stake represents ﹤0.01% of the portfolio and ranks #475 among its holdings.

19 funds tracked by Wall St. Rank hold BSEM as of Q3 2026.

Gables Capital Management held 350 shares of BioStem Technologies worth $1.08K as of Q3 2026.
BioStem Technologies was a new Gables Capital Management position in Q3 2026.
BioStem Technologies made up ﹤0.01% of Gables Capital Management's portfolio in Q3 2026, its #475 holding.
19 funds tracked by Wall St. Rank held BioStem Technologies as of Q3 2026.

Based on Gables Capital Management's 13F filing for Q3 2026, filed 4 Nov 2026.